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 Abstract 
KRAS is one of the most frequently mutated oncogenes in human non-small cell lung 
cancer (NSCLC). Mutations in KRAS are detected in 30% of NSCLC cases, with most 
of them occurring in codons 12 and 13 and less commonly in others. Despite intense 
efforts to develop drugs targeting mutant KRAS, no effective therapeutic strategies have 
been successfully tested in clinical trials. Here, we investigated molecular targets for 
KRAS-activated lung cancer cells using a drug library. A total of 1,271 small molecules 
were screened in KRAS-mutant and wild-type lung cancer cell lines. The screening 
identified the cytotoxic effects of benzimidazole derivatives on KRAS-mutant lung 
cancer cells. Treatments with two benzimidazole derivatives, methiazole and 
fenbendazole—both of which are structurally specific—yielded significant suppression 
of the RAS-related signaling pathways in KRAS-mutated cells. Moreover, 
combinatorial therapy with methiazole and trametinib, a MEK inhibitor, induced 
synergistic effects in KRAS-mutant lung cancer cells. Our study demonstrates that these 
benzimidazole derivatives play an important role in suppressing KRAS-mutant lung 
cancer cells, thus offering a novel combinatorial therapeutic approach against such 
cancer cells. 
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 1. Introduction 
Lung cancer is the leading cause of death worldwide, estimated to account for 
more than one million deaths per year [1]. Non-small cell lung cancer (NSCLC)—the 
main histological type comprising adenocarcinoma, squamous carcinoma, and large cell 
carcinoma—accounts for approximately 85% of all lung cancer cases [2]. Unfortunately, 
the prognosis of lung cancer remains dismal, with a five-year survival rate of 
approximately 15% [3]. Cytotoxic chemotherapy has improved the prognosis of both 
early- and advanced-stage NSCLC, and new advances in the discovery of oncogenic 
drivers as well as specific targeted therapies have yielded significant improvements in 
outcomes and quality of life of NSCLC patients [4]. 
In recent years, many studies have focused on mutations in epidermal growth 
factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) in NSCLC patients [5, 
6]. Specific targeted agents, such as gefitinib and crizotinib, designed to treat NSCLC, 
are known to be effective in patients [7, 8]. Mutations of the RAS family are detected in 
up to ~30% of human cancers, with 20–30% of NSCLC patients carrying KRAS 
mutations [9-11]. The function and importance of KRAS as a GTPase are evidenced 
from its role in connecting upstream signals from cell surface receptors, such as those in 
the FGFR and ERBB families to the MAPK cascade and other cancer-associated 
pathways [12]. Although KRAS signaling is a major oncogenic driver of lung cancers 
and is associated with a poor prognosis and therapy resistance, effective targeted 
therapy for KRAS-mutated lung cancer patients is currently lacking [13]. While indirect 
strategies such as synthetic lethality have emerged [14], novel treatment strategies to 
combat this major oncogenic mutation are urgently needed. 
Most studies in past decades have sought to develop drugs that target the 
downstream effectors of KRAS. Mutant-activated KRAS mediates several key 
 functions, including those involving intracellular signaling pathways that regulate cell 
proliferation, differentiation, and survival [15, 16]. Activation of KRAS leads to the 
stimulation of signaling pathways, including the PI3K/AKT and RAF/MEK/ERK 
pathways [17]. Several studies have demonstrated that mutations in the kinases of these 
so-called ‘canonical’ RAS signaling pathways are frequently observed in human cancer, 
identifying them as suitable therapeutic targets [18, 19]. With advances in molecular 
biology and high-throughput methodologies, as well as developments in genome 
sequencing, researchers now employ target-based screening for new drug discovery [20]. 
However, the target-based discovery of oncological drugs has been less successful than 
initially predicted. Reviews have shown that an alternative, phenotype-based approach 
with small molecule libraries has played a prominent role in the discovery of new 
chemical probes [21]. Consequently, there is a trend in drug discovery of cancer 
therapeutics toward phenotypic screening to provide greater confidence that the 
molecules discovered will deliver the desired therapeutic efficacy [22]. Small-molecule 
libraries that have a well-annotated pharmacology are suitable for phenotypic screening. 
Here, we used the Prestwick Chemical Library® (PCL)—a library comprising more 
than 1,200 drugs approved by the FDA, EMA, and other agencies. 
Based on our screening results using the chemical library, we identified the 
biological effects of benzimidazole derivatives, such as methiazole, fenbendazole, 
carbendazim, and benzimidazole itself on KRAS-mutant lung cancer cells. Moreover, 
we determined the molecular mechanism of these compounds. Our data provide novel 
insights for targeting KRAS-mutant lung cancer cells, thereby advancing the 
development of future therapeutics. 
  
 2. Materials and Methods 
2.1. Cell culture 
All the human lung cancer cell lines were purchased from American Type Culture 
Collection (ATCC, Manassas, VA, USA). Detailed information about the cell lines and 
culturing methods is described in Table S1. 
 
2.2. Drug treatment 
The Prestwick Chemical Library® was purchased from Prestwick Chemical 
(Illkirch-Graffenstaden, France). This library contains 1,271 small molecules, 95% of 
which are approved drugs (FDA, EMA, and other agencies). Methiazole was obtained 
from Latoxan (Portes-lès-Valence, France). Fenbendazole, benzimidazole, carbendazim, 
oxibendazole, mebendazole, albendazole, and fluticasone propionate were obtained 
from TCI Chemicals (Tokyo, Japan). Nocodazole was obtained from Wako (Tokyo, 
Japan). Estramustine was obtained from Sigma-Aldrich (St. Louis, MO, USA). 
Vemurafenib, dabrafenib, and trametinib were obtained from Selleck (Houston, TX, 
USA). The drugs were prepared at 10 µM by dissolving in DMSO for each analysis.  
 
2.3. Cell proliferation assay 
Cell proliferation was evaluated using the CellTiter-Glo® 2.0 Assay (Promega, Madison, 
WI, USA) as described in the manufacturer’s instructions. Each cell line was seeded in 
a 96-well white plate at 5.0 × 103 cells/well. Six hours after seeding the cells, the drugs 
were added at a 10-µM concentration. Forty-eight hours after for A-549 and 72 hours 
after for the other cell lines, the cells were measured using the CellTiter-Glo® 2.0 
reagent. Luminescence measurements were taken ten minutes after adding the agent 
using a microplate reader (BioTek, Gen5 Synergy™ H4, Winooski, VT, USA).  
  
2.4. Data analysis and visualization 
Beeswarms and boxplots were created using the beeswarm package and PCA maps 
were created using the ggplot2 package in the CRAN repository 
(http://cran.r-project.org/). Heatmaps of the Z-scores were generated using the publicly 
available software Morpheus (https://software.broadinstitute.org/morpheus/) and 
hierarchal clustering with the Euclidean distance and an average linkage method. Curve 
fitting and IC50 determinations were performed using the curve fitting analysis tool in 
Prism 7 (Version 7.0d, GraphPad Software, San Diego, CA, USA). Drug synergism was 
analyzed using CompuSyn (version 1.0) (http://www.combosyn.com/index.html), which 
is based on the combination index (CI) theorem of the Chou-Talalay method [23]. 
 
2.5. Immunofluorescence 
Cells were washed with PBS (-) three times and fixed in 4% paraformaldehyde (Wako) 
for 15 minutes at 25 ℃. The cells were again washed with PBS (-) three times and 
treated with 5% BSA (Sigma-Aldrich) and 0.1% Triton X-100 (Sigma-Aldrich) in PBS 
(-) overnight at 4 ℃. The cells were again washed with PBS (-) three times and treated 
with diluted Anti-Ki-67 antibody (1:250, Abcam, Cambridge, UK) with 5% BSA in 
PBS (-) for 1‒2 hours at 37 ℃. The staining results were imaged using a BZ-X700 
fluorescence microscope (Keyence, Osaka, Japan) using BZ-X analyzer software 
(Keyence). 
 
2.6. Apoptosis assay measurement in vitro 
To evaluate apoptotic activity, a luminescent caspase-3/7 activation assay was 
performed. The cells were seeded in a white 96-well plate; after six hours of incubation, 
 selected drugs were added at a concentration of 10 µM. After incubation for 48 to 72 
hours, Caspase-Glo® reagent (Caspase-Glo® 3/7 assay; Promega) was added and 
incubated for one hour, then the activity of caspase-3/7 was measured using a 
microplate reader (BioTek, Gen5 Synergy™ H4). 
 
2.7. Western blot analysis 
The cells were gently scraped from the culture plates, resuspended in 1,000 µL of 
M-PER buffer, and shaken for five minutes. The samples were then centrifuged at 
14,000 × g for ten minutes. The supernatants were collected and the protein 
concentration was calculated using a Qubit 2.0 Fluorometer (Thermo Fisher Scientific, 
Waltham, MA, USA). Protein extracts (30 µg per lane) were prepared and run on a 4‒
20% Mini-PROTEAN® TGX ™  gel (Bio-Rad, Hercules, CA, USA) or 7.5% 
Mini-PROTEAN TGX gel (Bio-Rad) then transferred to a 0.45-µm polyvinylidene 
difluoride (PVDF) membrane. The membranes were blocked for one hour at 25 ℃ using 
Blocking One (Nacalai Tesque, Kyoto, Japan) then incubated overnight at 4 ℃ with the 
primary antibodies shown in Table S2. Two secondary antibodies [Anti-Mouse IgG, 
HRP-Linked Whole Ab Sheep (GE Healthcare, Chicago, IL, USA); and Anti-Rabbit 
IgG, HRP-Linked Whole Ab Donkey (GE Healthcare)] were used at a dilution of 
1:5,000 and the membranes were developed using ImmunoStar LD (Wako) and imaged 
using the FUSION SOLO 7S (Vilber-Lourmat, Marne-la-Vallée, France). 
 
2.8. Crystal violet staining 
The cells were seeded in a 6-well plate at 2.0 × 104 cells/well. Six hours after seeding, 
the cells were treated according to the combinatorial administered dose. Forty-eight 
hours after culturing, the cells were washed with PBS (-) three times and fixed in 4% 
 paraformaldehyde (Wako) for 15 minutes at 25 ℃. The cells were then washed with 
PBS and stained with 0.5% crystal violet solution at 25 ℃ for 30 minutes. After rinsing 
with PBS, the plates were photographed using a digital scanner.  
 
2.9. Animal studies. 
All mouse experiments were approved by the National Cancer Center Research Institute, 
Institute of Laboratory Animal Research (Number: T18-009). Five-week-old female 
BALB/C nude mice were used for animal experiments. A-549 cells (KRAS-mutant) and 
H-1650 cells (wild-type) were injected into the right flank of the mice with 
matrigel/PBS (1.0 × 106 cells, 50% final concentration) of each mouse to establish 
xenograft models. One week after inoculation, each mouse was randomly separated into 
two groups (n = 6/group) of treatments with vehicle alone (olive oil with 3% DMSO) 
and with methiazole (total 720 µg/mouse) by intraperitoneal injection. Mice were 
monitored carefully and the size of their tumors was measured using a Vernier caliper. 
Tumors were harvested 19 days after inoculation of cancer cells and tumor weight was 
measured. 
 
2.10. Statistical analysis 
The data are presented as mean±SD. Statistical significance was determined using 
Student’s t-test. Differences were considered significant with a p value < 0.05. 
  
 3. Results 
3.1. Screening of small molecules to identify effective compounds for 
KRAS-mutant and wild-type cell lines 
To perform the screening to discover compounds effective for KRAS-mutant lung 
cancer cells, we first used three KRAS-mutant (A-549, H-23, and H-1573) and three 
wild-type (H-1650, H-522, and Calu-3) lung cancer cell lines (Fig. S1A). The screening 
procedure is summarized in Figure 1a. Cells seeded in a 96-well white plate were 
treated with 1,271 small molecules at a final concentration of 10 µM for each well. The 
library was selected because it contained small molecules approved by the FDA, EMA, 
and other agencies. The data were highly reproducible among independent experiments 
(Fig. S1B). All the cell lines were screened using the library, cell proliferation was 
evaluated using an ATP-based assay, and growth inhibition rates were assessed by 
Z-score analysis (Fig. 1b, Fig. S1C-G). The distributions of the number of compounds 
according to Z-score analysis obtained from the primary screening are shown in Figure 
1c and Figure S2A. Most of the compounds (> 80%) from the library that were not 
effective had a Z-score < 1 and the compounds with a Z-score ≥ 1 were considered for 
further experimental validation. The compounds with a Z-score ≥ 1 comprised 32% 
(24/75) oncological compounds and 6% (72/1,196) non-oncological compounds and the 
remainder contained many antitumor compounds, as expected (Fig. 1d). The results of 
the primary screening were visualized as a heatmap and were represented consistently 
with a histogram (Fig. 1e).  
 
3.2. Confirmation of the candidate compounds 
To investigate the inhibitory effect of compounds from the results of the primary 
screening, they were analyzed by principal component analysis (PCA). Figure 2a-c 
 shows the PCA map using Z-score analysis of the inhibitory effect of the compounds. 
The blue plots in Figure 2a show all the compounds and the difference between 
oncological (orange) and nononcological compounds (light blue) is shown in Figure 2b. 
The loading profile of PC1 at the x-axis suggests the inhibitory effect of the compounds 
for both KRAS-mutant and wild-type cells, and PC2 at the y-axis suggests the 
difference of an inhibitory effect of the compounds between KRAS-mutant and 
wild-type cells. The average Z-scores of all compounds for KRAS-mutant and 
wild-type cells are colored according to their distribution range (Fig. 2c). The 50 
top-ranked compounds of the average Z-score comprised 11 oncological compounds 
(15%, 11/75) and 39 nononcological compounds (3%, 39/1,196) (Fig. 2d). These results 
are similar to previous results (Fig. 1d), including commonly used chemotherapeutic 
agents. Figure 2e shows the effects of the oncological compounds from the top 50 on 
cell proliferation. All the top-ranked oncological compounds showed a significant 
inhibitory effect for both KRAS-mutant and wild-type cells; the results of the 
compounds and positive control (cisplatin) used for screening are shown in Figure S2B.  
 
3.3. KRAS-mutant cells are sensitive to benzimidazole derivatives 
Next, we focused on the difference in the compound effects between KRAS-mutant and 
wild-type cells from the results of the primary screening. An analysis of the Z-scores of 
the inhibitory effect of the compounds between KRAS-mutant and wild-type cells is 
shown in volcano plots (Fig. 3a). We identified eight compounds classified by a 
difference in the Z-score > 0.80 and p-value < 0.05 for subsequent validation assays. 
Figure 3b shows the heatmap representing the difference in the average Z-scores of the 
compounds between KRAS-mutant and wild-type cells. Intriguingly, we found a 
structural similarity among the selected compounds and most of them were 
 benzimidazole derivatives whose structural formulas are shown in Figure 3c. The eight 
selected compounds from the primary screening were tested by cell viability assays 
using ATP-based experiments; most of them showed a significant difference in their 
inhibitory effect on cell proliferation between KRAS-mutant and wild-type cells (Fig. 
3d, Fig. S3A and B). Taken together, our primary screening and validation assay results 
indicate that benzimidazole derivatives exhibit a significant difference in their 
inhibitory effect on cell proliferation between KRAS-mutant and wild-type cells. The 
more effective chemical compounds, methiazole and fenbendazole, were selected for 
further validation studies using additional cell lines (Fig. S3C).  
 
3.4. Methiazole and fenbendazole inhibit cell proliferation and induce apoptosis in 
KRAS-mutant cells 
Having demonstrated the effect of benzimidazole derivatives, we sought to perform 
further analysis for methiazole and fenbendazole. Among the benzimidazole derivatives 
that show an inhibitory effect on cell proliferation for KRAS-mutant cells, not all of 
them showed a significant difference between KRAS-mutant and wild-type cells. Given 
that the compounds with a simpler structure seem to be more effective, we selected 
methiazole and fenbendazole for subsequent experiments. To validate the effect of 
methiazole and fenbendazole on KRAS-mutant cells, we performed cell proliferation 
assays with additional cell lines (KRAS-mutant: A-427, H-1373, H-1734, H-2444, 
H-2347, A-549, H-23, and H-1573; wild-type: H-1395, H-1435, H-1838, H-2228, 
H-2286, H-1650, H-522, and Calu-3) (Fig. 4a and Fig. S3C). Both methiazole and 
fenbendazole showed a significant difference in their inhibitory effect between 
KRAS-mutant and wild-type cells. To further evaluate the function of benzimidazole 
derivatives, we performed immunofluorescence for Ki-67 of KRAS-mutant cell lines 
 (A-549 and H-23) and wild-type cell lines (H-1650 and H-2228) after treatment with 
methiazole and fenbendazole. Ki-67-positive cells were reduced significantly in 
KRAS-mutant cells compared to wild-type cells; furthermore, morphological changes 
were observed upon treatment with methiazole and fenbendazole, while no changes 
were observed upon treatment with DMSO (Fig. 4b and Fig. S4A). We next sought to 
determine the cellular effects (cytotoxicity or cytostasis) of methiazole and 
fenbendazole. Apoptosis after treatment with methiazole and fenbendazole was 
analyzed based on nuclear DNA fragmentation (Fig. S4). These experiments in other 
cell lines as well as treatment with fenbendazole also reduced Ki-67-positive cells (Fig. 
S4A and B). To confirm apoptotic cell death after the treatments, we performed a 
caspase 3/7 assay and nuclear DNA fragmentation counting. KRAS-mutant cells 
showed significantly higher caspase 3/7 activity and greater numbers of apoptotic cells 
than wild-type cells (Fig. S4C-E). These results suggest that benzimidazole derivatives 
inhibit cell proliferation and induce apoptosis via caspase 3/7 activity. The above results 
indicate that methiazole and fenbendazole have more inhibitory effects on 
KRAS-mutant cells than on wild-type cells and cause cytotoxicity via apoptosis. 
Regarding methiazole and fenbendazole, the IC50 was determined by inhibition curves 
drawn based on the results of the cell viability assay. We found that KRAS-mutant cells 
were more sensitive to methiazole (A-549: 1.9 µM; H-23: 0.6 µM) and fenbendazole 
(A-549: 1.5 µM; H-23: 0.4 µM), and the IC50 values were much lower than those of 
wild-type cells (methiazole = H-1650: > 40 µM, H-2228: > 40 µM; fenbendazole = 
H-1650: 6.2 µM, H-2228: 7.8 µM) (Fig. 4c and Fig. S5). We also evaluated the in vivo 
therapeutic effects of the benzimidazole derivatives in a subcutaneous xenograft model. 
We treated A-549 (KRAS-mutant) and H-1650 (wild-type)-xenografted mice with 
methiazole according to the protocol shown in Figure S6A. As expected, the tumor size 
 in A-549-xenografted mice was significantly decreased (Fig. 4d lower panels) while that 
in H-1650-xenografted mice was unchanged. Although the tumor weight tended to 
decrease in A-549-xenografted mice, the change was not statistically significant (Fig. 4d 
upper panels and S6B). 
 
3.5. Structural specificity of the benzimidazole derivatives 
To further understand the structural relationship between the benzimidazole derivatives 
and KRAS-mutant and wild-type cells, the effects of other benzimidazole derivatives 
were also examined. Given that methiazole and fenbendazole have relatively simple 
structures, these compounds were considered. Benzimidazole and carbendazim, two 
benzimidazole derivatives, are also structurally simple, and, were used for the analysis 
(Fig. S7A). To investigate the biological characteristics of benzimidazole and 
carbendazim, the same experiments as those for methiazole and fenbendazole were 
performed. From the results of an ATP-based cell proliferation assay, benzimidazole 
was found not to affect the cell proliferation in both KRAS-mutant and wild-type cells, 
while carbendazim inhibited cell proliferation but showed no difference between 
KRAS-mutant and wild-type cells (Fig. 5a). No effect was observed for Ki-67 
immunofluorescence and apoptotic cells treated with benzimidazole. Similar to the 
ATP-based cell proliferation assay, carbendazim inhibited cell proliferation and induced 
cell apoptosis, but there was no significant difference between KRAS-mutant and 
wild-type cells (Fig. 5b and Fig. S7B). Cell viability and caspase 3/7 activity were also 
consistent with the results described above (Fig. S7C and D). Furthermore, cell 
proliferation assays including compounds with an imidazole structure revealed that not 
all compounds demonstrated cytotoxicity and only certain compounds among the 
benzimidazole derivatives showed inhibitory effects on KRAS-mutant cells (Fig. 5c and 
 Fig. S7E). Importantly, methiazole exhibited almost no cytotoxic effects on normal 
epithelial cells compared with cisplatin (Fig. S7F), while fenbendazole possessed 
slightly higher cytotoxicity. According to these results, it was suggested that the 
structural components contained in methiazole and fenbendazole may contribute to 
RAS selectivity because no significance was observed in the analysis of benzimidazole 
and carbendazim between KRAS-mutant and wild-type cells. 
 
3.6. Methiazole and fenbendazole affect RAS signaling and exhibit synergy when 
combined with a MEK inhibitor 
To explore the differences in the mechanisms of these compounds between 
KRAS-mutant and wild-type lung cancer cells, we performed western blot analysis after 
treatment with methiazole, fenbendazole, benzimidazole, and carbendazim. We 
examined the status of the PI3K/AKT and RAF/MEK/ERK pathways to assess the 
effect of these compounds (Fig. 6a). Treatment of KRAS-mutant cells (H-23) with 
methiazole and fenbendazole simultaneously suppressed the PI3K/AKT pathway 
(confirmed by low levels of phosphorylated AKT), RAF/MEK/ERK pathway (verified 
by low levels of phosphorylated ERK), and Stat1 levels. SAPK, NFκB, and PI3Ks 
exhibited no specific differences upon treatment with the drugs (Fig. S8A). 
Benzimidazole and carbendazim showed little or no reduction effect in both 
KRAS-mutant and wild-type cells. These results indicate that benzimidazole derivatives, 
especially methiazole and fenbendazole, inhibit the PI3K/AKT and RAF/MEK/ERK 
pathways compared with the normal control (Fig. 6b).  
Given that methiazole and fenbendazole could partly suppress KRAS 
downstream signaling, the data prompted us to test the combinatorial effects of the 
benzimidazole derivatives with RAS signaling-related tyrosine kinase inhibitors such as 
 vemurafenib, dabrafenib, and trametinib. Upon various combinations of these drugs, 
most exerted synergistic effects at high concentrations (Fig. S8B); however, the 
combination of methiazole with trametinib, a MEK inhibitor, showed a maximum 
synergistic effect even at a low concentration based on the calculations using the 
median-effect principle and combination index-isobologram theorem (Fig. 6c and Fig. 
S9). Thus, the combinatorial treatment of methiazole and fenbendazole with tyrosine 
kinase inhibitors, especially trametinib, may offer a novel therapeutic strategy. 
 4. Discussion 
Despite years of developmental work on KRAS-mutant lung cancer, the 
effective targeting of the molecular driver of KRAS in lung cancer cells remains 
unsuccessful [24]. Extensive efforts have been directed toward the identification of new 
strategies, such as synthetic lethal target interactions with oncogenic KRAS-expressing 
cells [25, 26]. The identification of small molecules that affect KRAS or KRAS-related 
signaling pathways would be a step in this direction. Through drug library screening, we 
have demonstrated that benzimidazole derivatives serve as selective cytotoxic agents for 
KRAS-mutant lung cancer cells. Benzimidazole derivatives induce apoptotic cell death 
and inhibit KRAS-mutant lung cancer cell proliferation. We identified that methiazole 
and fenbendazole significantly inhibit the expression of the RAS-related signaling 
pathway in KRAS-mutant lung cancer cells. Consistent with the in vitro experiments, 
treatment with methiazole showed significant inhibitory effects in vivo. The 
combinatorial treatment of tyrosine kinase inhibitors, especially trametinib with 
methiazole, showed synergistic effects in KRAS-mutant lung cancer cells. Presently, 
there is no effective direct therapy for KRAS-mutant lung cancer cells though multiple 
strategies have been employed to identify such candidate inhibitors using 
high-throughput screening, fragment-based screening, or in silico screening [27]. Here, 
we showed the effectiveness of a phenotypic approach using a drug library and 
identified an effective combination strategy in KRAS-mutant lung cancer cells.  
As previously reported, benzimidazole derivatives are commonly used as 
anthelmintic therapeutics against roundworms and tapeworms in animals and humans 
[28, 29]. Recently, these compounds have been identified as potent anticancer agents 
and their mechanism of antitumor activity may be through the binding of tubulin [30, 
31], inhibition of poly (ADP-ribose) polymerase-1 (PARP-1) [32], topoisomerase I [33], 
 and tyrosine kinases [34]. Several studies have shown that benzimidazole derivatives 
may serve as novel agents for anticancer therapy [35]. Most of the clinically approved 
kinase inhibitors include bicyclic nitrogen heterocycles, but the benzimidazole scaffold 
interacts with kinases using multiple binding modes [36]. Regarding the recently 
developed molecular target therapeutic approach, some benzimidazole derivatives have 
been synthesized as kinase inhibitors, protein kinase CK2 (casein kinase 2) inhibitors 
[37], CDK9 (cyclin-dependent kinase 9) inhibitors [38], and multi target kinase 
inhibitors [34, 39]. Given that the benzimidazole derivatives identified in the primary 
screening exhibited antitumor effects and there are relatively few reports on methiazole 
and fenbendazole, we tried to assess their functional mechanisms. It is worth noting that 
methiazole and fenbendazole possess significant inhibitory effects on KRAS-mutant 
lung cancer cells. In the era of molecular target-based strategies in NSCLC, attempts to 
inhibit downstream effector pathways have shown only limited success [40]. However, 
the results of treatment with methiazole and fenbendazole in KRAS-mutant lung cancer 
cells clearly revealed the suppression of the PI3K/AKT and RAF/MEK/ERK pathways, 
both RAS-dependent pathways, indicating the underlying mechanism of the compound 
effects. The analysis of the structurally simpler compounds of benzimidazole 
derivatives, benzimidazole and carbendazim, as well as other compounds having an 
imidazole structure, showed that, among the benzimidazole derivatives, there is a 
structural specificity in the inhibitory effect on cell proliferation that differs between the 
presence and absence of KRAS mutation.  
 Combinatorial experiments with methiazole, fenbendazole, and tyrosine 
kinase inhibitors revealed synergistic effects for KRAS-mutant lung cancer cells (Fig. 
6c and Fig. S8B). Although most of the strategies targeting mutant KRAS had a low 
specificity or less therapeutic efficacy, treatment modalities based on synthetic lethal 
 interaction have been explored [25, 26, 41]. Given that methiazole and fenbendazole 
suppress the protein expression of AKT and ERK in the RAS-related signaling 
pathways of the RAF/MEK/ERK and PI3K/AKT pathways, we performed 
combinational experiments using several tyrosine kinase inhibitors. Synergistic 
cytotoxic effects on KRAS-mutant lung cancer cells were observed upon combination 
and methiazole or fenbendazole with trametinib, a MEK inhibitor, showed a highly 
synergistic effect at low concentration. As a substitute for a direct target to attack RAS 
proteins themselves, the MAPK pathway components RAF, MEK, and ERK and PI3K 
pathway components were expected to act as alternative targets. However, these 
pathways are much more complicated and various studies have attempted to confirm the 
interaction of these pathways [42-44]. Our data shed light on the ability of the 
combinatorial treatment of benzimidazole derivatives and a MEK inhibitor. Another 
study reported that a synthetic lethal approach targeting MEK and FGFR1 is effective 
for KRAS driven cancer cells [45]; however, further synergistic or synthetic lethal 
analysis for KRAS-related oncogenesis is warranted. 
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 Figure Legends 
Figure 1 
 
Screening to identify compounds from a small-molecule library that inhibits the 
proliferation of both KRAS-mutant and wild-type cells. a. Schematic overview of 
the protocol used for screening. b. Graph showing the Z-scores of the inhibitory effect 
of the compounds from the primary screen for A-549. c. Histogram of the Z-scores of 
the compounds for A-549. d. Ratio of the compounds with an average Z-score ≥ 1 in 
 oncological compounds and non-oncological compounds. e. Heatmap showing the 
effect of compounds in KRAS-mutant and wild-type cell lines.  
 
Figure 2 
 
Highly effective compounds from primary screening. a. PCA analysis of all screened 
compounds. b. PCA analysis of oncological compounds and nononcological compounds. 
c. PCA analysis of effective compounds for KRAS-mutant and wild-type cells. d. Fifty 
 top ranked compounds that inhibit cell proliferation. e. Inhibitory effect of the selected 
compounds in oncological fields relative to control. 
 
Figure 3 
 
Benzimidazole derivatives are more effective in KRAS-mutant cells. a. Difference 
in the effect of compounds between KRAS-mutant and wild-type cells. b. Clustering 
analysis of the selected compounds. c. Structure of the benzimidazole derivatives. d. 
 Quantitative effect of the selected compounds on cell proliferation. The values are mean 
± SD (n = 4). *, p < 0.05; **, p < 0.01; ***, p < 0.001; and n.s., not significant. 
 
Figure 4 
 
Methiazole and fenbendazole are more effective in KRAS-mutant cells. a. 
Quantification of the proliferation rate following treatment with methiazole and 
fenbendazole in KRAS-mutant and wild-type cells. The values are mean ± SD (n = 4). 
 **, p < 0.01; ***, p < 0.001. b. Effects of methiazole and fenbendazole on the 
proliferation of A-549 and H-2228 cells as determined by Ki-67 analyses. The values 
are mean ± SD (n = 3). *, p < 0.05; **, p < 0.01; ***, p < 0.001. c. The cells were 
treated with increasing doses of methiazole. Cell viability was determined using an 
ATP-based assay. The values are mean ± SD (n = 4). d. Quantitative analysis of tumor 
progression starting from the first instance at which a solid tumor mass was identified. 
Data shown are normalized to pretreatment tumor mass on day three from cell 
inoculation. Representative images of dissected tumors are shown in upper panels. The 
values are mean ± SD (n = 6). **, p < 0.01; and n.s., not significant. 
 
Figure 5 
  
Analysis of the structural differences in the benzimidazole derivatives. a. 
Quantification of the proliferation rate following treatment with benzimidazole and 
carbendazim in KRAS-mutant and wild-type cells. b. Effects of benzimidazole and 
carbendazim on the proliferation of A-549 and H-2228 cells as determined by Ki-67 
analyses. The values are mean ± SD (n = 3). n.s., not significant. c. Only certain 
compounds of benzimidazole derivatives showed inhibitory effects on both 
KRAS-mutant and wild-type cells. 
  
Figure 6 
 
Effects of methiazole and fenbendazole on RAS-related signaling. a. Western blot 
analyses of RAS-related signaling in H-23 and H-1650 cell lines treated with 
benzimidazole derivatives. b. Quantification of the blots of p-AKT, p-ERK, and Stat1. c. 
Image of the combinatorial experiment of methiazole and trametinib in A-549 cells. 
Data of the combinatorial experiment and combination index scores for A-549 cells 
 treated with methiazole and trametinib at the indicated concentrations.  
  
 Supplemental Information 
Figure S1 
 
Primary screening data.  
A. Morphological characteristics of KRAS-mutant cells (A-549, H-23, and H-1573) and 
wild-type cells (H-1650, H-522, and Calu-3). B. Linear progression of the luminescence 
of proliferation assays in two different experiments. Reproducibility of R2 values > 0.90. 
C-G. Graphs showing the Z-scores of the inhibitory effect of the compounds from the 
 primary screen on H-23, H-1573, H-1650, H-522, and Calu-3 cells. 
 
Figure S2 
 
Distribution of the screened compounds. A. Histogram of the Z-scores of the 
compounds for H-23, H-1573, H-1650, H-522, Calu-3 cells. B. Violin plot for the 
results of the Z-scores of the screening compounds and cisplatin.  
 
 Figure S3 
 
Detailed experimental results of the selected compounds. A, B. Cell viability and 
caspase activity in all cell lines after treatment with selected compounds from primary 
screening. C. Gene mutation status of the cell lines. 
 
Figure S4 
  
Effects of methiazole and fenbendazole on KRAS-mutant cell proliferation and 
apoptosis. A. Effects of methiazole and fenbendazole on the proliferation of A-549, 
H-23, H-1650, and H-2228 cells as determined by Ki-67 analyses at a low-power field. 
B. Effects of methiazole and fenbendazole on the apoptosis of A-549, H-23, H-1650, 
and H-2228 cells as determined by Hoechst 33258 staining at a low-power field. C. 
Ratio of caspase activity to the number of viable cells. D. The ratio of apoptotic cells in 
the A-549, H-23, H-1650, and H-2228 cells after treatment with methiazole and 
 fenbendazole was calculated as the number of apoptotic cells to the total cell number 
counted. The values are mean ± SD (n = 3). ***, p < 0.001. E. Caspase activity in the 
A-549, H-23, H-1650, and H-2228 cells after treatment with methiazole and 
fenbendazole was assessed using the caspase 3/7 assay. The values are mean ± SD (n = 
3). *, p < 0.05. 
 
Figure S5 
 
IC50 of fenbendazole. The cells were treated with increasing doses of fenbendazole. 
Cell viability was determined using an ATP-based assay. The values are mean ± SD (n = 
4).  
 
Figure S6 
  
Therapeutic effect of methiazole in a subcutaneous cancer xenograft model. A. 
Schematic protocol of the animal study. Subcutaneous xenograft mouse models were 
established with A-549 (KRAS-mutant) and H-1650 cells (wild-type). Methiazole (180 
mg / 200 µL olive oil) were injected intraperitoneal on day 6, 7, 12, 17 (total 720 mg). 
At the end of the treatment, tumors were harvested on day 19. B. Methiazole inhibited 
tumor growth as measured by tumor weights. The values are mean ± SD (n = 6).  
 
Figure S7 
  
Analysis of structurally similar compounds. A. Structure of benzimidazole and 
carbendazim. B. Effects of benzimidazole and carbendazim on the proliferation of 
A-549, H-23, H-1650, and H-2228 cells as determined by Ki-67 analyses at a 
low-power field. C. The ratio of apoptotic cells in the A-549, H-23, H-1650, and 
H-2228 cells after treatment with benzimidazole and carbendazim was calculated as the 
number of apoptotic cells to the total cell number counted. The values are mean ± SD (n 
= 3). n.s., not significant. D. Caspase activity in the A-549, H-23, H-1650, and H-2228 
 cells after treatment with benzimidazole and carbendazim was assessed using the 
caspase 3/7 assay. The values are mean ± SD (n = 3). n.s., not significant. E. Heatmap 
showing the effect of structurally similar compounds in KRAS-mutant and wild-type 
cell lines. F. The ratio of the caspase activity to the number of viable cells in normal 
epithelial cells treated with benzimidazole derivatives and cisplatin. 
 
Figure S8 
 
 Biological effects of benzimidazole derivatives and combinatorial effects with 
tyrosine kinase inhibitors. A. Western blot analyses of SAPK, NFκB, and PI3K levels 
in H-23 and H-1650 cell lines treated with benzimidazole derivatives. B. Image of the 
combinatorial experiment of methiazole and fenbendazole with trametinib, dabrafenib, 
vemurafenib in A-549 cells. The data of the combinatorial experiment and combination 
index scores for A-549 treated with fenbendazole and trametinib at the indicated 
concentrations. The values are mean ± SD (n = 3). 
 
Figure S9 
 
Caspase activity in combinatorial therapy. The data of the relative caspase activity of 
combinatorial experiment for A-549 treated with methiazole and fenbendazole with 
trametinib at the indicated concentrations. The values are mean ± SD (n = 3). 
  
Table S1 
 
Table S2 
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cancer Letters. 451, 2019 June 1. 
doi: 10.1016/j.canlet.2019.03.002. Epub 2019 Mar 9. 
2019 年 6 月 1 日 公表済 
